1. Electronic Orange Book. Bethesda, MD: U.S. Food and Drug Administration. www.fda.gov/cder/ob/default.htm. May 1, 2002 update.
     
  2. National Kidney Foundation Dialysis Outcomes Quality Initiative/Kidney Disease Outcomes Quality Initiative. NKF K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease . III. Iron Support. New York: National Kidney Foundation; 2000.
     
  3. Coyne DW, Adkinson NF, Nissenson AR, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-tolerant patients. Kidney Int. 2003;63:217–224.
     
  4. Lee GR. Iron deficiency and iron-deficiency anemia. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe’s Clinical Hematology. 10th ed. Baltimore, MD: Williams & Wilkins;1999:979–1010.
     
  5. Hudson JQ, Comstock TJ. Considerations for optimal iron use for anemia due to chronic kidney disease. Clin Ther. 2001;23:1637–1671.
     
  6. Jacobs A, Worwood M. Ferritin in serum: clinical and biochemical implications. N Engl J Med. 1975;292:951–956.
     
  7. Bainton DF, Finch CA. The diagnosis of iron deficiency anemia. Am J Med. 1964;37:62–70.
     
  8. Besarab A, Amin N, Ahsan M et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000;11:530–538.
     
  9. Fishbane S, Galgano C, Langley RC Jr, et al. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997;52:217–222.
     
  10. Mittman N, Sreedhara R, Mushnick R, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis. 1997;30:912–922.
     
  11. Jacobsson S. Clinical value of serum transferrin measurements. J Int Fed Clin Chem. 2001;13:1–8.
     
  12. Ahluwalia N, Skikne BS, Savin V, Chonko A. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Am J Kidney Dis. 1997;30:532–541.
     
  13. Chiang WC, Tsai TJ, Chen YM, et al. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin Nephrol. 2002;58:363–369.
     
  14. Chambers JK. Epoetin alfa: Focus on inflammation and infection. ANNA J (Nephrol Nurs J). 1998;25:353–356.
     
  15. Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis. 1997;29:319–333.
     
  16. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis. 1997;29:565–568.
     
  17. Definitions and Laboratory Assessment of Iron Status. Available at: http://www.ironpanel.org.au/AIS/AISdocs/labq1ab.htm.
     
  18. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26:41–46.
     
  19. Senger JM, Weiss RJ. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. ANNA J. 1996;23:319–323.
     
  20. Sunder-Plassmann G, Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant. 1995;10:2070–2076.
     
  21. Taylor JE, Peat N, Porter C, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 1996;11:1079–1083.
     
  22. Adamson JW. Epoetin alfa: into the new millennium. Semin Oncol. 1998;25(3 Suppl 7):76–79.
     
  23. Glasby J, Cavili I. Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology. 1999;13:461–488.
     
  24. Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized controlled trial. Ann Intern Med. 1997;126:782–787.

 

Watson Pharma, Inc